Onconova Therapeutics, Inc. is a Phase 3-stage biopharmaceutical company focused on discovering and developing novel small molecule drug candidates to treat cancer, with an initial focus on Myelodysplastic Syndromes (MDS). The Company has a pipeline of proprietary targeted agents designed to work against specific cellular pathways that are important in cancer cells. Advanced clinical trials with the Company’s lead compounds, IV and oral rigosertib, are aimed at what the Company believes are unmet medical needs of patients with MDS. In addition to rigosertib, Onconova is in pre-clinical development with ON 123300, a combination CDK4/6 and ARK5 inhibitor. Onconova is targeting additional solid tumor settings and medical indications as well.
Company HQ State:
Company HQ Country:
Main Therapeutic Focus:
Lead Product in Development:
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):